|
Gene: POMP |
Gene summary for POMP |
Gene summary. |
Gene information | Species | Human | Gene symbol | POMP | Gene ID | 51371 |
Gene name | proteasome maturation protein | |
Gene Alias | C13orf12 | |
Cytomap | 13q12.3 | |
Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9Y244 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51371 | POMP | GSM5353244_PA_PR5261_T2_S24_L002 | Human | Prostate | Tumor | 5.96e-18 | -8.08e-01 | 0.1569 |
51371 | POMP | P3_S6_AK | Human | Skin | AK | 1.13e-04 | -2.90e-01 | -0.3256 |
51371 | POMP | P4_S8_cSCC | Human | Skin | cSCC | 9.04e-09 | 1.21e-01 | -0.3095 |
51371 | POMP | P5_S10_cSCC | Human | Skin | cSCC | 1.47e-10 | 1.91e-01 | -0.299 |
51371 | POMP | P1_cSCC | Human | Skin | cSCC | 3.62e-57 | 2.03e+00 | 0.0292 |
51371 | POMP | P2_cSCC | Human | Skin | cSCC | 1.82e-37 | 1.49e+00 | -0.024 |
51371 | POMP | P4_cSCC | Human | Skin | cSCC | 2.60e-58 | 2.07e+00 | -0.00290000000000005 |
51371 | POMP | P10_cSCC | Human | Skin | cSCC | 3.74e-63 | 2.56e+00 | 0.1017 |
51371 | POMP | cSCC_p4 | Human | Skin | cSCC | 2.51e-03 | 1.18e-03 | -0.2022 |
51371 | POMP | cSCC_p7 | Human | Skin | cSCC | 2.83e-08 | -3.52e-01 | -0.2332 |
51371 | POMP | cSCC_p8 | Human | Skin | cSCC | 2.86e-11 | 8.99e-02 | -0.1971 |
51371 | POMP | cSCC_p9 | Human | Skin | cSCC | 1.84e-15 | -4.12e-03 | -0.1991 |
51371 | POMP | Adj_PTCwithHT_6 | Human | Thyroid | HT | 3.10e-07 | -4.22e-01 | 0.02 |
51371 | POMP | Adj_PTCwithHT_8 | Human | Thyroid | HT | 2.43e-04 | -4.07e-01 | 0.0267 |
51371 | POMP | PTCwithHT_6 | Human | Thyroid | HT | 5.51e-07 | -3.91e-01 | 0.02 |
51371 | POMP | PTCwithHT_8 | Human | Thyroid | HT | 1.16e-09 | -4.32e-01 | 0.0351 |
51371 | POMP | PTCwithoutHT_2 | Human | Thyroid | PTC | 3.91e-12 | -4.81e-01 | 0.0419 |
51371 | POMP | PTCwithoutHT_7 | Human | Thyroid | PTC | 1.39e-02 | -4.47e-01 | 0.0381 |
51371 | POMP | male-WTA | Human | Thyroid | PTC | 9.95e-72 | -1.52e-01 | 0.1037 |
51371 | POMP | nodule-WTA | Human | Thyroid | goiters | 3.01e-05 | -5.10e-01 | 0.0534 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004324811 | Esophagus | ESCC | proteasome assembly | 11/8552 | 12/18723 | 1.26e-03 | 6.06e-03 | 11 |
GO:0043248 | Liver | Cirrhotic | proteasome assembly | 9/4634 | 12/18723 | 3.59e-04 | 3.03e-03 | 9 |
GO:00432481 | Liver | HCC | proteasome assembly | 12/7958 | 12/18723 | 3.46e-05 | 3.45e-04 | 12 |
GO:00432482 | Oral cavity | OSCC | proteasome assembly | 11/7305 | 12/18723 | 2.45e-04 | 1.57e-03 | 11 |
GO:00432484 | Skin | cSCC | proteasome assembly | 10/4864 | 12/18723 | 5.36e-05 | 5.38e-04 | 10 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0305010 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0305013 | Breast | Precancer | Proteasome | 25/684 | 46/8465 | 4.35e-16 | 9.81e-15 | 7.52e-15 | 25 |
hsa0305022 | Liver | HCC | Proteasome | 43/4020 | 46/8465 | 2.62e-11 | 4.61e-10 | 2.56e-10 | 43 |
hsa0305032 | Liver | HCC | Proteasome | 43/4020 | 46/8465 | 2.62e-11 | 4.61e-10 | 2.56e-10 | 43 |
hsa0305020 | Oral cavity | OSCC | Proteasome | 42/3704 | 46/8465 | 1.32e-11 | 2.01e-10 | 1.02e-10 | 42 |
hsa03050110 | Oral cavity | OSCC | Proteasome | 42/3704 | 46/8465 | 1.32e-11 | 2.01e-10 | 1.02e-10 | 42 |
hsa0305026 | Oral cavity | LP | Proteasome | 41/2418 | 46/8465 | 1.05e-17 | 3.17e-16 | 2.05e-16 | 41 |
hsa0305036 | Oral cavity | LP | Proteasome | 41/2418 | 46/8465 | 1.05e-17 | 3.17e-16 | 2.05e-16 | 41 |
hsa0305018 | Prostate | BPH | Proteasome | 28/1718 | 46/8465 | 2.01e-09 | 2.89e-08 | 1.79e-08 | 28 |
hsa0305019 | Prostate | BPH | Proteasome | 28/1718 | 46/8465 | 2.01e-09 | 2.89e-08 | 1.79e-08 | 28 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
POMP | SNV | Missense_Mutation | c.12A>T | p.Arg4Ser | p.R4S | Q9Y244 | protein_coding | tolerated_low_confidence(0.08) | benign(0.073) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
POMP | SNV | Missense_Mutation | c.396N>C | p.Leu132Phe | p.L132F | Q9Y244 | protein_coding | tolerated(0.05) | benign(0.443) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
POMP | SNV | Missense_Mutation | c.373N>A | p.Glu125Lys | p.E125K | Q9Y244 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
POMP | SNV | Missense_Mutation | novel | c.34G>T | p.Asp12Tyr | p.D12Y | Q9Y244 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.879) | TCGA-VS-A9V4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
POMP | SNV | Missense_Mutation | rs148838797 | c.112N>C | p.Val38Leu | p.V38L | Q9Y244 | protein_coding | deleterious(0.01) | benign(0.159) | TCGA-AG-A00C-01 | Colorectum | rectum adenocarcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
POMP | SNV | Missense_Mutation | c.373G>A | p.Glu125Lys | p.E125K | Q9Y244 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
POMP | SNV | Missense_Mutation | c.86N>C | p.Asp29Ala | p.D29A | Q9Y244 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
POMP | SNV | Missense_Mutation | novel | c.392N>T | p.His131Leu | p.H131L | Q9Y244 | protein_coding | deleterious(0.04) | possibly_damaging(0.773) | TCGA-AP-A0LS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
POMP | SNV | Missense_Mutation | c.380N>C | p.Met127Thr | p.M127T | Q9Y244 | protein_coding | deleterious(0) | benign(0.029) | TCGA-B5-A11J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
POMP | SNV | Missense_Mutation | novel | c.35N>G | p.Asp12Gly | p.D12G | Q9Y244 | protein_coding | tolerated_low_confidence(0.06) | benign(0.283) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |